PAGE Therapeutics is a platform-based oncology drug development company. Our mission is to discover and commercialize anti-metastatic compounds to improve and prolong the lives of cancer patients.
Metastasis has always accounted for most cancer-related deaths. This needs to change.
Circulating tumor cell clusters (CTC clusters) are responsible for the formation of metastases.
CTC clusters are multicellular groupings of cancer cells held together through adhesion molecules.
CTC clusters are highly efficient pioneers of the metastatic process. Their presence highlights patients with a poor prognosis.
Currently, no drugs exist to target CTC clusters or prevent their formation.
We have identified compounds that target CTC clusters and block the spread of cancer.
New chemistry with highest cluster-dissolution activity identified
Daniele Scarinci serves as the Chief Executive Officer at PAGE Therapeutics and is a co-founder and Managing Partner at XGen Venture, a venture capital fund management company specializing in the life science sector.
With over 15 years of experience in the life science sector, Daniele has held executive positions at Genextra, where he served as Investment Director, and as CEO at Tethis for a period of two years.
Prior to his roles in the life science industry, he held several strategic and financial planning collaborations in different industries (retail, tlc, media, tech, etc.), and business planning and investor relations in e.Biscom/Fastweb.
Daniele’s academic background includes a cum laude degree in Economics of Financial Markets from Rome University of Tor Vergata.
Prof. Dr. Nicola Aceto
Nicola Aceto is co-founder, Chief Science Officer at PAGE Therapeutics and Professor of Molecular Oncology at ETH Zurich.
He contributed to key discoveries in the metastasis field, namely identifying circulating tumor cell (CTC) clusters as critical pioneers of the metastatic process. These scientific discoveries represent the foundational scientific framework of PAGE Therapeutics.
Nicola has received numerous awards for his work on CTC clusters, including the Swiss Science Prize Latsis for Groundbreaking Cancer Research, the EACR Translational Cancer Research Award and the Friedrich Miescher Award for Outstanding Achievements in Biochemistry.
Before joining ETH Zurich and PAGE Therapeutics, he has been SNSF Professor at the University of Basel.
He has completed his training at the Friedrich Miescher Institute (FMI), Massachusetts General Hospital Cancer Center and Harvard Medical School.
Prof. Dr. Med. Christoph Rochlitz
Christoph Rochlitz is co-founder and Chief Medical Officer of PAGE Therapeutics and Professor Emeritus of Medical Oncology at the University of Basel.
He studied medicine at the universities of Heidelberg (D), Berlin (D), Montpellier (F) and Cambridge (UK).
His training in medical oncology included internships and positions as a senior physician in medical oncology at the University Hospitals of Heidelberg, Berlin and Basel (CH), as well as postdoctoral laboratory research at the University of California, San Francisco (USA) and the Institut Pasteur in Paris (F).
During his career, Christoph was involved in numerous phase I, II and III clinical trials in solid tumors, focusing on breast cancer.
Until his retirement in 2022, he was Head of Oncology and President of the Cancer Centre at the University Hospital Basel.
Christoph was also Head of the Breast Centre at the University Hospital Basel and President of the Breast Cancer Project Group of the SAKK (Swiss Association for Clinical Cancer Research, SGCCR).
Prof. Dr. Med. Johann De Bono
London, Institute of Cancer Research & The Royal Marsden NHS Foundation Trust
Prof. Dr. Med. Reinhard Dummer
Zürich, Comprehensive Cancer Center (CCCZ)
Prof. Dr. Med. Florian Lordick
Leipzig, University Cancer Centre (UCLL)
Prof. Dr. Med. Beat Thürlimann
St. Gallen, Kantonsspital
Prof. Dr. Med. Andrew Tutt
London, King’s College & ICR
Prof. Dr. Med. Michael Zelefsky
New York, Memorial Sloan Kettering Cancer Center (MSKCC)